✚ Evidence in focus

ALLEVYN◊ Ag+ SURGICAL Foam Dressing demonstrates superior rapid and sustained microbial killing ability in vitro for up to 7 days versus other silver-containing dressings[1]

Smith+Nephew

Overview

- In the United States, surgical site infections (SSI) affect ~500,000 surgical patients each year, leading to ~8,000 deaths annually[2]
  - A patient with an SSI has a 2–11x increase in mortality compared to a patient without a post-surgical SSI[2]
  - SSI was identified as the most common reason for hospital readmission in 346 hospitals across the United States[3]
- The silver foam layer and carbon of ALLEVYN Ag+ SURGICAL Dressing provides effective antimicrobial action, with sustained antimicrobial activity over 7 days on a broad range of wound-relevant pathogens*[4]

Methodology[1]

Bacterial, yeast and fungal microbial species were cultured



Dressings were pre-conditioned in simulated wound fluid (SWF)

SWF containing the microbial species were applied to the dressing and number of viable organisms were analysed after a given time period

Results[1]

Significant microbial killing with ALLEVYN Ag+ SURGICAL Dressing versus other dressings at:



Conclusion

ALLEVYN Ag+ SURGICAL Dressing demonstrated superior killing of multiple microbial species, including both gram positive and negative bacteria, yeast, and fungus, versus other silver-containing dressings at 1 hour and 7 days.

*As demonstrated in vitro. †p<0.001 for all comparisons, except Aquacel™ Ag+ Advantage Surgical for *P. aeruginosa* at 4 hours. ‡p<0.05 for all comparisons, except Mepilex™ Border Ag Post-op for *P. aeruginosa*.

Abbreviations: MRSA = methicillin-resistant *Staphylococcus aureus*.

References: 1. Smith+Nephew 2024. Internal report CSD.AWM.24.081. **2.** Najjar PA, Smink DS. *Surg Clin North Am.* 2015;95(2):269–283. **3.** Merkow RP, Ju MH, Chung JW, et al. *JAMA.* 2015;313(5):483–495. **4.** Smith+Nephew 2024. Internal report CSD.AWM.24.019.

Advanced Wound Management, Smith & Nephew Medical Ltd, 101 Hessle Road, Hull HU3 2BN, UK.
46280-en V2 05/25. Published May 2025.

Developed by Evidence Communications,
Global Clinical & Medical Affairs
www.smith-nephew.com